期刊文献+

片剂工艺验证中应用失效模式和影响分析的风险评估

Risk Assessment in Process Validation of Tablets by Failure Mode and Effects Analysis
原文传递
导出
摘要 目的探索失效模式和影响分析(FMEA)在片剂工艺验证中的应用,降低验证风险。方法 FMEA应用于氢溴酸右美沙芬片的工艺验证,分析生产过程中的关键影响因素,评估关键因素对产品质量的影响,确定风险等级以及制定风险控制措施。结果验证结束后风险优先系数(RPN)值减小,降低了质量风险。结论 FMEA可有效用于片剂工艺验证的风险评估,降低生产质量风险。 OBJECTIVE To explore the application of failure mode and effects analysis( FMEA) in the tablets process validation and in order to reduce the risk of process validation of tablets. METHODS Application of FMEA in the process validation of Dextromethorphan Hydrobromide Tablets,analyzed the key factors in the process of production,assessed their impact on product quality,determined the risk grades,and set up the risk control measures. RESULTS The results showed that risk priority number( RPN) value decreased after process validation,indicating that the quality risk of product was reduced. CONCLUSION FMEA can be effectively used in the tablets process validation.
作者 胡卫林 HU Weilin(Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., Guangzhou , Guangdong 510285, China)
出处 《今日药学》 CAS 2017年第9期620-625,共6页 Pharmacy Today
关键词 氢溴酸右美沙芬片 风险评估 工艺验证 失效模式和影响分析 dextromethorphan hydrobromide tablets risk assessment process validation failure mode and effects analysis
  • 相关文献

参考文献2

二级参考文献10

  • 1国家食品药品监督管理局药品监管安全司等组织编写.药品生产质量管理规范(2010年修订)培训教材[M].天津:天津科学技术出版社,2011:393-394.
  • 2International Standard. Analysis techniques for systemreliability- Procedure for failure mode and effects analysis (FMEA) [S]. IEC 60812: 2006.
  • 3EU guidelines to good manufacturing practice medicinal products for human and veterinary use, Annex 20, Quality Risk Management[S]. Brussels, 2008: 14.
  • 4U.S. Food and Drug Administration. Guidance for Industry Process Validation: General Principles and Practices. [S/OL]. 2011-1.http://www.fda.gov/downloads/drugs/guidancecomplia nceregulatoryinformation/guidances/ucm070336.pdf.
  • 5卫生部.药品生产质量管理规范2010年修订[S/OL].2011-01-17.http://www.sda.gov.cn/WSO1/CLO053/585009.html.
  • 6卫生部.药品生产质量管理规范2010年修订.原料药附录[S/OL]. 2011-02-24. http://www.ccd.org.crdccdweb/main?fid= open& fun=show_news& from=view&nid=5346.
  • 7GB/T7826-2012.可靠性分析技术失效模式和影响分析(FMEA)程序[S].2012:1-22.
  • 8International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Quality Risk Management. Q9 [S/OL]. 2005-11. http://www.ich.org/products/ guidelines/quality/article/quality-guidelines.html.
  • 9肖江宜,平其能.质量风险管理在药品GMP现场检查中运用的探讨[J].中国新药杂志,2009,18(19):1826-1830. 被引量:5
  • 10朱富根.浅谈大容量注射剂的风险管理[J].中国药物警戒,2010,7(8):477-481. 被引量:3

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部